Glenmark Pharmaceuticals reaches agreement with Pfizer for Axitinib Tablets

27 Nov 2022 , 01:34 AM

Glenmark Pharmaceuticals Inc USA Glenmark and Glenmark Pharmaceuticals have reached a settlement agreement with Pfizer Inc PF Prism CV and PF Prism IMB BV Pfizer for Axitinib Tablets 1 mg and 5 mg the generic version of their Inlyta1 Tablets 1 mg and 5 mg Glenmark had previously announced it received tentative approval by the United States Food Drug Administration USFDA for their generic Axitinib Tablets 1 mg and 5 mg on 30 November 2020 According to IQVIATM sales data for the 128208;month period ending September 2022 the Inlyta Tablets 1 mg and 5 mg market achieved annual sales of approximately $6445 million